WHOCC
Postal address:
WHO Collaborating Centre for Drug Statistics Methodology
Norwegian Institute of Public Health
P.O.Box 4404 Nydalen
0403 Oslo
Norway

Visiting/delivery address:
Marcus Thranes gate 6
0473 Oslo
Norway

Tel:  +47 21 07 81 60
E-mail:
 
Copyright/Disclaimer

New ATC

Overview of new ATC codes decided at the two previous meeting of the WHO International Working Group for Drug Statistics Methodology. Comments or objections to the ATC codes from the latest meeting (temporary codes) should be forwarded to the WHO Collaborating Centre for Drug Statistics Methodology within the deadline. If no objections are received, the new ATC codes will be considered final and included in the ATC/DDD Index. The year of implementation in the ATC/DDD Index is given in the list.

Please note that the list does not include new ATC codes established as a result of ATC alterations.

ATC codeATC level name (INN/generic name)Deadline for objection to temporary code 1) Implementation in the ATC/DDD index
V03AB38andexanet alfa01.09.20172018
C10BX15atorvastatin and perindopril01.09.20172018
S01XA24cenegermin01.09.20172018
A11CC55colecalciferol, combinations01.09.20172018
N07BA04cytisine01.09.20172018
J05AR21dolutegravir and rilpivirine01.09.20172018
L01XC28durvalumab01.09.20172018
B02BX06emicizumab01.09.20172018
J05AR20emtricitabine, tenofovir alafenamide and bictegravir01.09.20172018
J05AR22emtricitabine, tenofovir alafenamide, darunavir and cobicistat01.09.20172018
N02CX07erenumab01.09.20172018
L01XC29ermekumab01.09.20172018
A10BH07evogliptin01.09.20172018
C09DA10fimasartan and diuretics01.09.20172018
R03AL09formoterol, glycopyrronium bromide and beclometasone01.09.20172018
L04AC16guselkumab01.09.20172018
R07AX31ivacaftor and tezacaftor01.09.20172018
S01XA25lifitegrast01.09.20172018
A10BD22metformin and evogliptin01.09.20172018
M09AX07nusinersen01.09.20172018
N02AA56oxycodone and naltrexone01.09.20172018
A06AX07plecanatide01.09.20172018
M01AH07polmacoxib01.09.20172018
L03AB15ropeginterferon alfa-2b01.09.20172018
L04AC15sirukumab01.09.20172018
J05AP56sofosbuvir, velpatasvir and voxilaprevir01.09.20172018
D01AE24tavaborole01.09.20172018
A16AB18vestronidase alfa01.09.20172018
R03AL08vilanterol, umeclidinium bromide and fluticasone furoate01.09.20172018
R03DX10benralizumabFinal2018
L01XE 41binimetinibFinal2018
L01XE43brigatinibFinal2018
A16AB17cerliponase alfaFinal2018
D11AH05dupilumabFinal2018
M09AX06eteplirsenFinal2018
L01XX56etirinotecan pegolFinal2018
N02AA53hydromorphone and naloxoneFinal2018
A16AB16idursulfase betaFinal2018
A10AE54insulin glargine and lixisenatideFinal2018
N05BX05Lavandulae aetheroleumFinal2018
V10XX04lutetium (177Lu) oxodotreotideFinal2018
R03DA12mepyramine theophyllinacetateFinal2018
A16AX14migalastatFinal2018
S01EX05netarsudilFinal2018
L01XX54niraparibFinal2018
J06BB22obiltoxaximabFinal2018
L01XC27olaratumabFinal2018
N04BX04opicaponeFinal2018
D06AX14ozenoxacinFinal2018
L01XD07padeliporfinFinal2018
L03AA17pegteograstimFinal2018
L01XX57plitidepsinFinal2018
C09BX03ramipril, amlodipine and hydrochlorothiazideFinal2018
A02BX14rebamipideFinal2018
L01XE 42ribociclibFinal2018
M05BX06romosozumabFinal2018
C10BX14rosuvastatin, amlodipine and perindoprilFinal2018
C10BX13rosuvastatin, perindopril and indapamideFinal2018
L01XX55rucaparibFinal2018
A10BJ06semaglutideFinal2018
V03AE10sodium zirconium cyclosilicateFinal2018
J05AX69 2)sofosbuvir and velpatasvirFinal2018
N05CM19suvorexantFinal2018
N01BA53tetracaine, combinationsFinal2018
A16AB15velmanase alfaFinal2018
J07BK03zoster, purified antigenFinal2018
1) Final: indicates that the date for objection has expired
2) The ATC code will be altered to J05AP55 in connection with the implementation of the new ATC 4th level J05AP Antivirals for treatment of HCV infections in 2018.

New ATC level codes (other than 5th levels)

ATC codeATC level nameDeadline for objection to temporary alterations Implementation in ATC/DDD index
J05APAntivirals for treatment of HCV infectionsFinal2018

Last updated: 2017-05-09